Views

CrossRef citations to date

Altmetric

LETTERS TO THE EDITOR: MEDICAL ONCOLOGY

Patients’ preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406

Go MakimotoDepartment of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

Katsuyuki HottaCenter of Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan; ;Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan; Correspondence[email protected]

Isao OzeDivision of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan;

Kiichiro NinomiyaDepartment of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

Masamoto NakanishiDepartment of Respiratory Medicine, Yamaguchi Ube Medical Center, Ube, Japan;

Naofumi HaraDepartment of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

Hirohisa KanoDepartment of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

Hiromi WatanabeDepartment of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

Yusuke HataDepartment of Respiratory Medicine, Kure Kyosai Hospital, Kure, Japan;

Kazuya NishiiDepartment of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

Takamasa NakasukaDepartment of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

Junko ItanoDepartment of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

Takashi NinomiyaHealth Service Center, Okayama University, Okayama, Japan;

Toshio KuboCenter for Clinical Oncology, Okayama University Hospital, Okayama, Japan;

Kadoaki OhashiDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan;

Eiki IchiharaDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan;

Daisuke MinamiDepartment of Respiratory Medicine, Okayama Medical Center, Okayama, Japan

Akiko SatoDepartment of Respiratory Medicine, Okayama Medical Center, Okayama, Japan

Masahiro TabataCenter for Clinical Oncology, Okayama University Hospital, Okayama, Japan;

Yoshinobu MaedaDepartment of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

Katsuyuki KiuraDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan;

show all

Click to increase image sizeClick to decrease image size

Acknowledgments

This study was conducted with support from the Centre for Innovative Clinical Medicine, Okayama University Hospital. We thank the following investigators and all other investigators at Okayama University Hospital: Drs. Yosuke Toyota, Satoru Senoo, Takahiro Umeno, Naohiro Oda, Hisao Higo, Chihiro Ando, Atsuko Hirabae, Yoshitaka Iwamoto, and Kammei Rai. We also thank Drs. Mikio Kataoka and Masafumi Fujii as members of the Data and Safety Monitoring Board. We are also thankful to Hiromi Matsushita and Kaori Ohashi for supporting this study.

Disclosure statement

K.H. reports grants and personal fees from AZ, grants and personal fees from Lilly, grants and personal fees from BMS, personal fees from MSD, personal fees from Ono, personal fees from NipponKayaku, personal fees from Taiho, personal fees from BI, and personal fees from Chugai outside the submitted work. K. K. has received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, and Sanofi-Aventis. The remaining authors report no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Patients’ preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406

Related Research Data

Information for

Open access

Opportunities

Help and information

Patients’ preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406

Acknowledgments

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related Research Data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature